Bush C, Price P, Norton J, Parkins C S, Bailey M J, Boyd J, Jones C R, A'Hern R P, Horwich A
Radiotherapy Research Unit, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK.
Br J Cancer. 1991 Aug;64(2):357-60. doi: 10.1038/bjc.1991.306.
Ki-67 is a monoclonal antibody which recognises a human nuclear antigen expressed in proliferating cells. The antibody was used to assess proliferation in primary human bladder tumours from 64 patients. Ki-67 index (the number of Ki-67 positive tumour cells divided by the total number of tumour cells %) was derived from 59 tumours. A wide range of Ki-67 indices were recorded, range 3.0-65.8%, mean 20.2%. The Ki-67 index correlated with known prognostic factors: T stage (P = 0.002) and histological grade (P less than 0.001), early stage disease and more differentiated tumours having lower Ki-67 indices. Patients with invasive disease (21 patients) had significantly higher Ki-67 indices than those with non-invasive disease (P = 0.01). Patients with metastatic disease at presentation (four cases) all had a Ki-67 index of greater than or equal to 29%. Ki-67 antibody staining is a simple technique for assessing the proliferation fraction than can be performed on a small amount of tissue taken at routine biopsy without prior injection of thymidine analogues.
Ki-67是一种单克隆抗体，可识别在增殖细胞中表达的一种人类核抗原。该抗体用于评估64例原发性人类膀胱肿瘤中的增殖情况。Ki-67指数（Ki-67阳性肿瘤细胞数除以肿瘤细胞总数的百分比）来自59个肿瘤。记录到的Ki-67指数范围很广，为3.0 - 65.8%，平均为20.2%。Ki-67指数与已知的预后因素相关：T分期（P = 0.002）和组织学分级（P小于0.001），早期疾病和分化程度更高的肿瘤具有较低的Ki-67指数。浸润性疾病患者（21例）的Ki-67指数显著高于非浸润性疾病患者（P = 0.01）。初诊时患有转移性疾病的患者（4例）的Ki-67指数均大于或等于29%。Ki-67抗体染色是一种评估增殖分数的简单技术，可在常规活检获取的少量组织上进行，无需事先注射胸腺嘧啶类似物。
